Compare ES & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ES | WST |
|---|---|---|
| Founded | 1927 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7B | 20.2B |
| IPO Year | N/A | N/A |
| Metric | ES | WST |
|---|---|---|
| Price | $67.86 | $277.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $70.83 | ★ $345.75 |
| AVG Volume (30 Days) | ★ 2.5M | 692.4K |
| Earning Date | 02-10-2026 | 02-12-2026 |
| Dividend Yield | ★ 4.48% | 0.32% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | 3.65 | ★ 6.75 |
| Revenue | ★ $13,148,536,000.00 | $3,017,900,000.00 |
| Revenue This Year | $10.35 | $7.01 |
| Revenue Next Year | $4.68 | $6.20 |
| P/E Ratio | ★ $18.44 | $40.82 |
| Revenue Growth | ★ 13.12 | 4.92 |
| 52 Week Low | $52.28 | $187.43 |
| 52 Week High | $75.25 | $348.90 |
| Indicator | ES | WST |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 54.79 |
| Support Level | $64.12 | $272.53 |
| Resistance Level | $68.18 | $279.01 |
| Average True Range (ATR) | 1.04 | 5.88 |
| MACD | 0.18 | 0.70 |
| Stochastic Oscillator | 78.50 | 88.61 |
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric and gas distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. The company exited most of its unregulated businesses in 2006.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.